<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E227415-0DCC-48DC-B2DA-CB325D7515FD"><gtr:id>1E227415-0DCC-48DC-B2DA-CB325D7515FD</gtr:id><gtr:name>US Dept of Energy</gtr:name><gtr:address><gtr:line1>1000 Independence Avenue</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D9D173EA-C6E0-451C-8438-F29BF99FF5D3"><gtr:id>D9D173EA-C6E0-451C-8438-F29BF99FF5D3</gtr:id><gtr:name>Macquarie University</gtr:name><gtr:address><gtr:line1>Macquarie University</gtr:line1><gtr:line4>North Ryde</gtr:line4><gtr:postCode>NSW 2109</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E227415-0DCC-48DC-B2DA-CB325D7515FD"><gtr:id>1E227415-0DCC-48DC-B2DA-CB325D7515FD</gtr:id><gtr:name>US Dept of Energy</gtr:name><gtr:address><gtr:line1>1000 Independence Avenue</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D9D173EA-C6E0-451C-8438-F29BF99FF5D3"><gtr:id>D9D173EA-C6E0-451C-8438-F29BF99FF5D3</gtr:id><gtr:name>Macquarie University</gtr:name><gtr:address><gtr:line1>Macquarie University</gtr:line1><gtr:line4>North Ryde</gtr:line4><gtr:postCode>NSW 2109</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6E3E3635-ED48-40A3-A8DA-3C19F94A1AB6"><gtr:id>6E3E3635-ED48-40A3-A8DA-3C19F94A1AB6</gtr:id><gtr:firstName>Laura</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Piddock</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501415"><gtr:id>1228C1B1-0C4D-40DA-94C2-608ECBE97295</gtr:id><gtr:title>Unravelling multiple antibiotic resistance in Salmonella enterica</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501415</gtr:grantReference><gtr:abstractText>We are performing experiments that will allow us to understand how salmonella bacteria become multi-drug (antibiotic) resistant (MDR) after exposure to antibiotics. 
Every year people are exposed to salmonella and some people get ill. The very old and young are particularly vulnerable to this infection and they may be so sick that they need antibiotics to help them recover. Treatment of antibiotic resistant salmonella can be difficult. 
One way in which bacteria can resist antibiotic action is to pump the drug out of the cell. This is why some bacteria are always resistant to some drugs. Some MDR salmonella produce even more of these pumps than normal strains, making these MDR strains additionally resistant to antibiotics. Whilst we know the identity of some of these pumps, we do not know what controls when they are produced, or what makes the bacterium produce more. 
New methods allow us to look at what happens to bacteria when we have removed or ?knocked out? the pump. Other methods allow us to both inactivate, and label, the antibiotic resistance. By doing this the DNA sequence, and hence the gene/s involved, are found.
Understanding how MDR is caused will allow us to develop screening tests to quickly identify this type of resistance. Inhibitors of the pumps or genes that control their production can also be developed.</gtr:abstractText><gtr:technicalSummary>Non-typhoidal Salmonella enterica (NTS) are major human pathogens. The morbidity of NTS infections is ~60% and the fatality rate of NTS ~1-4%. For the elderly and very young this rate is increased, especially in the developing world where the numbers of invasive strains of NTS are increasing; antibiotic resistance increases rates 2 fold. Chronic and extra-intestinal infections require antibiotic therapy, but the numbers of antibiotic resistant NTS are increasing making therapy problematic. Bacteria can be multiply antibiotic resistant (MAR) via the constitutive over-expression of chromosomally encoded efflux pumps. Several publications indicate that over expression of E. coli marA or soxS, and/or the efflux pump AcrAB-TolC system are associated with MAR, however our work shows that the same is not always true for NTS. We will examine four hypotheses (i) MAR can be due to over expression of one or more efflux pumps possibly in synergy with an OMP involved with influx, mediated by over expression of a transcriptional activator; (ii) ramA is the transcriptional activator that mediates MAR; (iii) MAR can be chromosomally mediated by two mechanisms, only one of which also confers cyclohexane tolerance; and (iv) Efflux mediated MAR occurs in high numbers of naturally occurring antibiotic resistant NTS. We predict that there are two mechanisms of resistance of MAR: altered gene expression or mutation conferring a change in transporter substrate specificity. Two strategies to identify the cause of MAR will be pursued, one using microarrays to determine the gene expression profile of stable constitutive isogenic MAR mutants compared with the parent strain, SL1344; the second strategy will clone MAR from two mutants. The regulon of ramA will also be explored. Genes that are differentially expressed specific to phenotype will be disrupted and then complemented to determine their role, if any, in MAR. Even if differential expression is observed, it may not lead to easily identifiable genes for disruption thereby necessitating cloning of MAR into pBLUESCRIPT and electroporation into E. coli DH5 alpha. Representative MAR clones will be transformed into SL1344 and MAR genes characterised. Finally, human and animal isolates of NTS will be screened to determine the prevalence of the identified mechanism(s) of MAR.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>309565</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>U.S. Department of Energy</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Pacific Northwest National Laboratory</gtr:department><gtr:description>Jason McDermott</gtr:description><gtr:id>2BC30411-F24F-4EBA-B9EF-337C5848B766</gtr:id><gtr:impact>Data analysed and hypothesis for further work derived</gtr:impact><gtr:outcomeId>543f82b598dc80.23359596-1</gtr:outcomeId><gtr:partnerContribution>Analysis of data</gtr:partnerContribution><gtr:piContribution>Provided large data sets</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Macquarie University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Ian Paulsen</gtr:description><gtr:id>288A4F7C-69E8-4AB3-BAF4-4213EFDD2237</gtr:id><gtr:impact>Data analysed and hypothesis for further work derived</gtr:impact><gtr:outcomeId>543f836bd29f24.76432200-1</gtr:outcomeId><gtr:partnerContribution>Analysis of data sets</gtr:partnerContribution><gtr:piContribution>Provide large data sets</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference Talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>74564073-D34C-4BC3-B657-387051F708A7</gtr:id><gtr:impact>08/09/16 Microbiology Society AGM Microbiology Society, London Prize winner lecture From outreach to basic research - addressing the crisis of AMR
28/09/16 Resistance and You! PHE, University of Manchester Speaker All about antibiotics - how they have changed our world
28/09/16 Resistance and You! PHE, University of Manchester Panel Chair Antibiotics and You!
07/11/16 Chevening leadership Foundation: R&amp;amp;D policy and strategies for innovation Chevening Foundation, London Speaker An overview of AMR, the scale of the problem and possible solutions
16/11/16 Plugging the Antibiotics Gap: A Medicinal Chemist's Perspective Royal Pharmaceutical Society, Alderley park, Cheshire Plenary speaker The global challenge of antibacterial drug resistance: what can be done?
13/01/17 Early Discovery of new antibiotics EU JPI AMR, Paris Panel Chair Analysis of the current European level portfolio: how to synergize the approaches, how to progress for new strategies / optimize funding around discovery
07/02/17 SHAMROCK annual lecture University of Sheffield Speaker Multi drug efflux systems: from basic research to discovering efflux inhibitors</gtr:impact><gtr:outcomeId>58c29430bfc000.38569933</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2D62FA7C-5906-49D4-A009-B16696C30175</gtr:id><gtr:impact>460 students attended the lecture which sparked questions and discussions afterwards

-</gtr:impact><gtr:outcomeId>Jw1R1nYdX7n</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>718A1BE7-0A87-4C52-A4A0-9CDF49DCA85F</gtr:id><gtr:impact>Two day workshop on bacterial infections.

Children wrote poems, did artwork.</gtr:impact><gtr:outcomeId>2DFBB2BFBB8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media actitivies</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2A295338-ADCE-445D-BD1A-7E69743A9BDF</gtr:id><gtr:impact>Professor Laura Piddock gave interviews to local, national and international media (TV, Radio and print). In the last 12 months this has included: 
BBC Newsnight 
BBC Radio 4 
Live interview with Channel 4 
Sky News live interviews
Numerous Interviews about teixobactin including The Jeremy Vine Show, BBC Radio 2 (Jan 2015)
? Provided quote to The Independent (March 2015)
? Provided quotes to The Times, The Telegraph and The Independent on 'AncientBiotics' (March 2015).
? Letter to The Times,' Britain faces an 'antibiotic Armageddon' (April 2015)
? Filming for Panorama (April 2015)
? Interview with BBC Radio 4 'The Report' (April 2015)
BBC R4 Today x3

Various TV interviews syndicated worldwide including to CNN.
Global media coverage (quoted &amp;gt;200 times) following the WHO's report on 30 April 2014.
Federation of Infection Societies annual meeting: interview for short film: What is the cost of not developing another antibacterial drug
Numerous print and online media interviews including The Times, The Telegraph, The Daily Mail, The Daily Express, The Metro. Quotations have often been repeated in worldwide media including in USA print media.
BBC Horizon (broadcast 22 May 2014)
Swiss National Science Foundation (SNSF) National Research Programme (NRP) Steering Committee with the title &amp;quot;Antimicrobial Resistance: a one-health approach&amp;quot;
Plenary lecture at the 'Stimulating Antimicrobial Innovation' one day meeting at the NHLI, Imperial College London on October 22nd 2015. This is being organised by the Academy of Pharmaceutical Sciences GB, through the focus group on Microbiology and Anti-infectives. 
Board of Examiners in Biochemistry and Biotechnology at Imperial College London, I am writing to invite you to join us as an External Examiner for our BSc courses commencing with the 2015/16 academic year
Invitation to be a panellist at BioInfect 2015
Guest lecture on antibiotic resistance for a new course we are developing as part of the University of Glasgow online learning course.
Plenary Lecture Invitation: Research Day-St George's University of London 2 Dec talk on the subject of 'The challenges of AMR' at the launch of our new EPSRC funded AMR 'Bridging the Gaps' launch event University of Loughborough 7 Dec
Swedish Research Council review panel to evaluate applications for a Networking call to bring together researchers from Sweden and India on e-Science for Life Science and Antibiotic resistance in a 'One Health' perspective
Science Foundation Ireland review panel, Dublin SFI Investigators Programme 25th and 26th of February 2016.
European Science Foundation Invitation to join Review Panel on AXA postdoctoral fellowships 2016 meetings in Feb and May 2016
ZIBI Interdisciplinary Center for Infection Biology and Immunity
 Symposium Therapeutic Resistances in Infectious Disease - Status Quo and Future Challenges, Berlin (June 27/28, 2016
Science Representative of the Buckinghamshire Federation of Women's Institutes to warmly invite you to speak at our science Investigation and Discovery Day on 7 March, in Aylesbury
Invitation to Convene and speak in symposium: 2016 ASM Microbe plenary session
Plenary lecture on AMR at the IPS conference September 2016 
'Turn your nose up' campaign with the Farms not Factories organisation
 Took part in a written panel interview which will appear in Future Medicinal Chemistry's upcoming New Frontiers in Antimicrobial Drug Discovery special issue
? Interviewed by Bloomberg News, Australia
? Invited to interview with The Naked Scientist
Flix Interactive about a Wellcome Trust funded project on an antimicrobial resistance computer game
? Release of BSAC policies on antimicrobial use in animals and humans (May).
? Interviewed by The Atlantic on the O'Neill Report, LJVP, (May).
? Interviewed by BBC Radio 4 Today programme (1:22), LJVP (May).
? Interviewed by BBC2 Victoria Derbyshire programme (May).
? Interviewed by BBC Radio 4 Today programme (2:25) LJVP, (May).
? Interviewed by BBC World on superbugs, LJVP, (May). 
? Invited to interview by Good Morning Britain about the O'Neill Report, LJVP, (May)
? Interviewed by Kevin Fong, National Geographic, LJVP (May).
? Interviewed by Bang! Oxford University's Science Magazine, LJVP (May).
? Interviewed by a 7th grader for a project on antibiotic resistance, LJVP (May).
? Interviewed by the Daily Mail Good Health, LJVP (May).
? Provided comment to Science Media Centre on colistin-resistant bacteria in US woman, LJVP (May).
? Invited to attend the UK premier of the documentary &amp;quot;Clean Hands&amp;quot;, 28th June, London, LJVP (May).
? Invited to interview by The Los Angeles Times, LJVP (June).
? BBC Radio 4 'In our Time' programme, Penicillin, 9th June 2016, LJVP (June).
? Invited to interview by &amp;quot;Sputnik - Orbiting the World with George Galloway&amp;quot;, LJVP (June)
? Invited to write an article for The Conversation, LJVP (June).
? Reviewed and edited the script for a cartoon series generated by the Dundee Design School, LJVP (June).
? Invited to write an article for the Spanish newspaper 'El Pa&amp;iacute;s, LJVP (June).
? Provided a quote to the British Medical Journal for a feature on the impact of NICE sepsis guidance on antibiotic subscribing, LJVP (June).
? Provided NICHE with Antibiotic Action posters.
? Invited to join expert panel for Innovate UK and Department of Health Funding competition: antimicrobial resistance, 29th November (Oct)
? Invited by the Food Standards Agency and the Universities of Southampton and Newcastle, to participate in a joint antimicrobial resistance workshop. (Oct)
? Invited to give a plenary lecture on antimicrobial resistance at the St George's Annual Research Day. (Oct)
? Interviewed by the Sunday Express. (Oct)
? Interview with Strategy&amp;amp; for a 'State of the Nation report' into AMR research &amp;amp; development in the UK. (Oct)
? Invited to provide quotes to the Bureau of Investigative Journalism on the topic of antimicrobial resistance. (Oct)
? Attended the 75th anniversary of penicillin, 7 November, University of Oxford. (LJVP) 
? Invited to appear and provide expertise in a BBC4 documentary with Michael Moseley
? Supplement in the Guardian (Media Planet) under the One Health Agenda
? Twitter: True Stories on video joint release with PHE (stories embargoed by PHE plus BBC Radio 4 stories and Tony Maxwell videos
? Interview with Good Housekeeping magazine for WAAW
? Invited to provide a comment on 'everyday germs in the home, their effects and how you can reduce the risk of illness' for a campaign run by Domestic Innovations. (July)
? Working with BBC Five Live on concerns in relation to availability of antibiotics via online pharmacies. 
? Invited to provide comment for a story the Guardian are covering that looks at an antibiotic that kills Staphylococcus aureus. (July)
? Invited to interview with TIME magazine about the anthrax outbreak in Russia
? To provide expertise on a script for a feature film under development by Neon Films
? To provide a quote for the cover of a forthcoming science book by the Royal Society of Chemistry 'The Microbes Fight Back: Antibiotic Resistance' 
? Interviewed by James Gallagher, BBC Health website - UN Resolution. (Sept)
? Interview with BBC Radio 5 Live Drive - UN Resolution. (Sept)
? Interviewed with Deutsche Welle Television, Berlin - UN Resolution. (Sept)
? Interviewed by The Lancet Infectious Disease on UN Resolution to be published in November. (Sept)
? Interview with BBC World Service - The Inquiry to discuss the antibiotics crisis, following the recent UN meeting.
? Interview with BBC News - UN Resolution. (Sept


Promotion of Antibiotic Action (AA) being led by Prof. Laura Piddock. Antibiotic Action is a global initiative by the British Society for Antimicrobial Chemotherapy (BSAC) to highlight the threat to world health from multi-drug resistant bacteria and lobby for urgent action to develop new antimicrobial treatments</gtr:impact><gtr:outcomeId>grw6h3Ms5FW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1282168</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B913F36A-4449-4B19-BEFE-5842EA937AFF</gtr:id><gtr:outcomeId>Mvco6m1yGhn0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Medical Research Council Cross Funder AMR committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>63057334-4C16-4024-903E-A98899E65968</gtr:id><gtr:outcomeId>5453a67da9a2d0.57115396</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Antibiotic Strategy, Department of Health</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FD35E729-7EF4-44F1-831C-00E461C4D0D6</gtr:id><gtr:outcomeId>W9UiZivWpgs</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Longitude Prize Expert Advisory Panel</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7DDD6F81-F7EF-4FC6-AE25-754129490AC2</gtr:id><gtr:outcomeId>5453a76a5c18f4.77840136</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Secreteriat APPG on Antibiotics</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F9177BD6-3D56-4666-8498-92AAD3C16ECB</gtr:id><gtr:outcomeId>kFCaC5YS3Gp</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Antibiotic Action</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B273A7CD-C212-48F2-BCE9-EF00785A8820</gtr:id><gtr:outcomeId>aoWsC8dDsh5</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BSAC, The Urgent Need for New Antibiotics</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2EABFE25-7960-4C0F-92A7-42D0E6361FA3</gtr:id><gtr:outcomeId>oRZBNbXSD46</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisor to CMO on antibiotics</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DDBDD424-4C08-40A7-9296-969EE222A48B</gtr:id><gtr:outcomeId>qhcpWgkXxyN</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>O'Neil AMR Review</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>06D08799-79D0-4339-A21A-0A5C4FC1A549</gtr:id><gtr:outcomeId>56c1c61358d272.19276500</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EU Joint Programming Initiative on AMR Scientific Advisory Board</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BA1B91A5-1A42-48CE-8F9C-10D599D7652A</gtr:id><gtr:outcomeId>5453a47c83bae7.30675788</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3E3850F0-7EC0-452C-A50F-61FFC9875857</gtr:id><gtr:title>Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8271175496db39b403df5fbed395c3ef"><gtr:id>8271175496db39b403df5fbed395c3ef</gtr:id><gtr:otherNames>Redgrave LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>545397c08f76a1.06425644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4679F1E3-A0CE-4DCF-B97C-DDDC63C2B02D</gtr:id><gtr:title>Ciprofloxacin selects for multidrug resistance in Salmonella enterica serovar Typhimurium mediated by at least two different pathways.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc6abb924dee6661a8b8ebc5febb488"><gtr:id>fbc6abb924dee6661a8b8ebc5febb488</gtr:id><gtr:otherNames>Ricci V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>2880EF15829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D8FC73-15C1-47D9-B20D-E1BA14A2FCE8</gtr:id><gtr:title>CsrA maximizes expression of the AcrAB multidrug resistance transporter.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc6abb924dee6661a8b8ebc5febb488"><gtr:id>fbc6abb924dee6661a8b8ebc5febb488</gtr:id><gtr:otherNames>Ricci V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5a82e0bf76ed69.98853300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DC6BACA-FD95-4365-A6FA-7034D2B1AFE4</gtr:id><gtr:title>AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19aeca31db2156b30e754efe006dd3a2"><gtr:id>19aeca31db2156b30e754efe006dd3a2</gtr:id><gtr:otherNames>Blair JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_55f983983ba65140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA7AC1A9-BE5F-4A45-B469-69C0551DC2F6</gtr:id><gtr:title>RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4127020a5ed78268187bf98313553cc"><gtr:id>d4127020a5ed78268187bf98313553cc</gtr:id><gtr:otherNames>Bailey AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>ADCAC0871D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B42DF550-C0E5-4106-8BC5-0280D40D758F</gtr:id><gtr:title>Beyond Antimicrobial Resistance: Evidence for a Distinct Role of the AcrD Efflux Pump in Salmonella Biology.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a5dc85f5b2aa84250a1ee4a54b083a3"><gtr:id>0a5dc85f5b2aa84250a1ee4a54b083a3</gtr:id><gtr:otherNames>Buckner MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b42cd064f569.63527471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7168B4FD-597A-4B15-BFD8-752086A04DB3</gtr:id><gtr:title>Understanding the basis of antibiotic resistance: a platform for drug discovery.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2547011783a4a3f8679e33cd84f2d4b8"><gtr:id>2547011783a4a3f8679e33cd84f2d4b8</gtr:id><gtr:otherNames>Piddock LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn><gtr:outcomeId>5453979444b371.63831237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5F0ABE5-EA4D-466B-8E80-DE8D700E89E3</gtr:id><gtr:title>Regulation of the AcrAB-TolC efflux pump in Enterobacteriaceae.</gtr:title><gtr:parentPublicationTitle>Research in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bc6e6d096437be21636d06b2d29ad5f"><gtr:id>8bc6e6d096437be21636d06b2d29ad5f</gtr:id><gtr:otherNames>Weston N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0923-2508</gtr:issn><gtr:outcomeId>5a85a70ea33d63.03220396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F621EA0F-D067-4DFA-81AA-4F31B971F455</gtr:id><gtr:title>Only for substrate antibiotics are a functional AcrAB-TolC efflux pump and RamA required to select multidrug-resistant Salmonella Typhimurium.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc6abb924dee6661a8b8ebc5febb488"><gtr:id>fbc6abb924dee6661a8b8ebc5febb488</gtr:id><gtr:otherNames>Ricci V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>goFNMEHECF8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4169550F-6200-4431-952A-02FDC66CF1F8</gtr:id><gtr:title>The TCA cycle is not required for selection or survival of multidrug-resistant Salmonella.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc6abb924dee6661a8b8ebc5febb488"><gtr:id>fbc6abb924dee6661a8b8ebc5febb488</gtr:id><gtr:otherNames>Ricci V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14026_26_22186876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02D499C0-8E05-4F83-BBF9-4CA6FEDE483F</gtr:id><gtr:title>Clinically relevant mutant DNA gyrase alters supercoiling, changes the transcriptome, and confers multidrug resistance.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63dd6bbb5971117dc0b87c2772e59f2a"><gtr:id>63dd6bbb5971117dc0b87c2772e59f2a</gtr:id><gtr:otherNames>Webber MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_14026_26_23882012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B48ABF03-66C3-4AD8-B974-5C2A193B58DB</gtr:id><gtr:title>RamA, a member of the AraC/XylS family, influences both virulence and efflux in Salmonella enterica serovar Typhimurium.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4127020a5ed78268187bf98313553cc"><gtr:id>d4127020a5ed78268187bf98313553cc</gtr:id><gtr:otherNames>Bailey AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>L6Q52qoVHdm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4261E29E-AF26-4587-ABD3-F5A887456B11</gtr:id><gtr:title>Expression of homologous RND efflux pump genes is dependent upon AcrB expression: implications for efflux and virulence inhibitor design.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19aeca31db2156b30e754efe006dd3a2"><gtr:id>19aeca31db2156b30e754efe006dd3a2</gtr:id><gtr:otherNames>Blair JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>543f810d438a33.21191349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>335DA1C0-3423-4605-A99D-7554DE827A5C</gtr:id><gtr:title>Choice of bacterial growth medium alters the transcriptome and phenotype of Salmonella enterica Serovar Typhimurium.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19aeca31db2156b30e754efe006dd3a2"><gtr:id>19aeca31db2156b30e754efe006dd3a2</gtr:id><gtr:otherNames>Blair JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14026_26_23704954</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501415</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>